Actively Recruiting
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Led by Qlaris Bio, Inc. · Updated on 2026-02-24
14
Participants Needed
1
Research Sites
14 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
CONDITIONS
Official Title
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of mild to moderate open-angle glaucoma, mild to moderate normal tension glaucoma, or stable non-proliferative diabetic retinopathy in at least one eye.
- Corrected visual acuity in each eye of +1.0 logMAR or better (equivalent to 20/200) using ETDRS.
- Able and willing to give signed informed consent and follow study instructions.
You will not qualify if you...
- History of active eye disease other than mild to moderate open-angle glaucoma, mild to moderate normal tension glaucoma, or stable non-proliferative diabetic retinopathy.
- Using more than one ocular hypotensive topical medication for intraocular pressure control.
- Use of topical beta-blockers such as timolol within 3 months prior to screening.
- Noncompliance with ocular anti-hypotensive medications or unwillingness to comply during the study.
- Severe retinal disease requiring treatment during the study, such as proliferative diabetic retinopathy, exudative or severe non-exudative macular degeneration.
- Anti-VEGF or topical steroid treatment within 3 months prior to screening or expected treatment during the study.
- Corneal changes that prevent accurate intraocular pressure measurements.
- Clinically significant systemic or psychiatric diseases that may affect study results or safety, including stages 3-5 kidney disease or estimated glomerular filtration rate below 59.
- Use of calcium channel blockers.
- Uncontrolled labile hypertension or hypotension.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University, Dept. of Ophthalmology
Palo Alto, California, United States, 94303
Actively Recruiting
Research Team
L
Lisa Brandano
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here